Zileuton for Food Allergy

Inclusion Criteria:

• Adolescent subjects ages 12-17

• Parent or guardian fluent in English

• Known IgE-mediated food allergy other than peanut

  • Confirmed by clinical history of reaction to the food antigen plus

    1. positive skin prick testing and/or serum food-specific IgE AND
    2. confirmation of the food allergy diagnosis by a board-certified allergist

Exclusion Criteria:

• A previous positive peanut specific IgE test or skin prick test, or a history of any allergic symptoms following peanut consumption
• Medical conditions known to affect the gastrointestinal tract
• Any history of hepatic disease or previous abnormal liver function tests
• Previous hypersensitivity or anaphylaxis to zileuton
• Current use of a medication known to interact with zileuton, such as theophylline, warfarin, or propranolol
• History of drug or alcohol abuse
• Use of any investigational drugs within 30 days of screening
• Initiation of allergen immunotherapy within 3 months prior to Visit 1 or a plan to begin therapy during the trial
• Use of leukotriene antagonists/modifier such as montelukast
• Pregnant persons
• Individuals with uncontrolled neuropsychiatric disorders
• Use of oral corticosteroids (OCS) within 2 weeks before screening or are scheduled to receive OCS during the study period for another condition
• Monoclonal antibody or immunosuppressive treatment within 3 months of screening
• Past or current medical problems which in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or may compromise the quality of the data obtained from the study
• Inability or unwillingness of a parent or guardian to give written informed consent or participant to give assent
• Non-English speaking participants